Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts by Novo Nordisk to ramp up its production capacity for semaglutide. The Danish drugmaker has asked the FDA to move ...

Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form. The importance of biosimilars only continues to grow ...